Neumora Therapeutics Inc (NAS:NMRA)
$ 1.255 -0.060 (-4.58%) Market Cap: 235.81 Mil Enterprise Value: 171.29 Mil PE Ratio: 0 PB Ratio: 5.21 GF Score: 11/100

Neumora Therapeutics Inc NMRA-511 Update Conference Call Transcript

Jan 05, 2026 / 01:00PM GMT
Release Date Price: $1.64 (-1.51%)
Operator

Ladies and gentlemen, thank you for standing by. (Operator Instructions) Please be advised that today's event is being recorded. I would now like to turn the call over to Helen Rubenstein, Vice President, Investor Relations and Communications at Neumora. Please go ahead.

Helen Rubinstein
Neumora Therapeutics Inc - IR Contact Officer

Good morning, everyone, and thank you for joining us today to discuss top-line data from the Phase Ib signal-seeking study with NMRA-511 in Alzheimer's disease agitation. Before we begin, I'd like to point out that this presentation contains forward-looking statements, which are based on our current expectations and beliefs. We have a number of important disclosures on this slide, which we urge you to read. With me today are several members of Neumora's management team, including Co-Founder, Chief Executive Officer and Chairman, Paul Burns; President, Josh Pinto; Chief Scientific Officer, Nick Brandon; and Chief Operating and Development Officer, Bill Aurora. With that, I'll now turn the call over to Paul to begin. Paul?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot